|
| 36353934 | Microglia and astrocyte activation is region-dependent in the α-synuclein mouse model of Parkinson's disease. | Glia | 2023 |
| 36353934 | Microglia and astrocyte activation is region-dependent in the α-synuclein mouse model of Parkinson's disease. | Glia | 2023 |
| 37584601 | Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways. | Cancer Discov | 2023 |
| 37802053 | TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory. | Cancer Cell | 2023 |
| 37188783 | Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. | Nat Med | 2023 |
| 37061388 | Oncolytic virotherapy for the treatment of pediatric brainstem gliomas. | Rev Neurol (Paris) | 2023 |
| 37244226 | Translational considerations for immunotherapy clinical trials in pediatric neuro-oncology. | Neoplasia | 2023 |
| 37541723 | Oncolytic viruses as treatment for adult and pediatric high-grade gliomas: On the way to clinical success. | Int Rev Cell Mol Biol | 2023 |
| 37802053 | TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory. | Cancer Cell | 2023 |
| 37584601 | Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways. | Cancer Discov | 2023 |
| 37541723 | Oncolytic viruses as treatment for adult and pediatric high-grade gliomas: On the way to clinical success. | Int Rev Cell Mol Biol | 2023 |
| 37061388 | Oncolytic virotherapy for the treatment of pediatric brainstem gliomas. | Rev Neurol (Paris) | 2023 |
| 37188783 | Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. | Nat Med | 2023 |
| 37244226 | Translational considerations for immunotherapy clinical trials in pediatric neuro-oncology. | Neoplasia | 2023 |
| 34965961 | Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory. | Mol Cancer Ther | 2022 |
| 35393952 | Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas. | JCI Insight | 2022 |
| 35902132 | Reshaping the tumor microenvironment with oncolytic viruses, positive regulation of the immune synapse, and blockade of the immunosuppressive oncometabolic circuitry. | J Immunother Cancer | 2022 |
| 35767439 | Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma. | N Engl J Med | 2022 |
| 35949950 | Galectin-3 inhibition boosts the therapeutic efficacy of Semliki Forest virus in pediatric osteosarcoma. | Mol Ther Oncolytics | 2022 |
| 35493490 | Immunovirotherapy for Pediatric Solid Tumors: A Promising Treatment That is Becoming a Reality. | Front Immunol | 2022 |
| 36142368 | The Comparative Experimental Study of Sodium and Magnesium Dichloroacetate Effects on Pediatric PBT24 and SF8628 Cell Glioblastoma Tumors Using a Chicken Embryo Chorioallantoic Membrane Model and on Cells In Vitro. | Int J Mol Sci | 2022 |
| 35625705 | Different Effects of Valproic Acid on <i>SLC12A2</i>, <i>SLC12A5</i> and <i>SLC5A8</i> Gene Expression in Pediatric Glioblastoma Cells as an Approach to Personalised Therapy. | Biomedicines | 2022 |
| 35481923 | The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies. | Neuro Oncol | 2022 |
| 36321133 | DNA-damaging cancer cells to improve virotherapy. | Mol Ther Oncolytics | 2022 |
| 35216113 | The Different Temozolomide Effects on Tumorigenesis Mechanisms of Pediatric Glioblastoma PBT24 and SF8628 Cell Tumor in CAM Model and on Cells In Vitro. | Int J Mol Sci | 2022 |
| 34965961 | Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory. | Mol Cancer Ther | 2022 |
| 35481923 | The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies. | Neuro Oncol | 2022 |
| 35767439 | Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma. | N Engl J Med | 2022 |
| 35493490 | Immunovirotherapy for Pediatric Solid Tumors: A Promising Treatment That is Becoming a Reality. | Front Immunol | 2022 |
| 35393952 | Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas. | JCI Insight | 2022 |
| 35625705 | Different Effects of Valproic Acid on <i>SLC12A2</i>, <i>SLC12A5</i> and <i>SLC5A8</i> Gene Expression in Pediatric Glioblastoma Cells as an Approach to Personalised Therapy. | Biomedicines | 2022 |
| 36142368 | The Comparative Experimental Study of Sodium and Magnesium Dichloroacetate Effects on Pediatric PBT24 and SF8628 Cell Glioblastoma Tumors Using a Chicken Embryo Chorioallantoic Membrane Model and on Cells In Vitro. | Int J Mol Sci | 2022 |
| 35902132 | Reshaping the tumor microenvironment with oncolytic viruses, positive regulation of the immune synapse, and blockade of the immunosuppressive oncometabolic circuitry. | J Immunother Cancer | 2022 |
| 35949950 | Galectin-3 inhibition boosts the therapeutic efficacy of Semliki Forest virus in pediatric osteosarcoma. | Mol Ther Oncolytics | 2022 |
| 36321133 | DNA-damaging cancer cells to improve virotherapy. | Mol Ther Oncolytics | 2022 |
| 35216113 | The Different Temozolomide Effects on Tumorigenesis Mechanisms of Pediatric Glioblastoma PBT24 and SF8628 Cell Tumor in CAM Model and on Cells In Vitro. | Int J Mol Sci | 2022 |
| 33376098 | Delta-24-RGD, an Oncolytic Adenovirus, Increases Survival and Promotes Proinflammatory Immune Landscape Remodeling in Models of AT/RT and CNS-PNET. | Clin Cancer Res | 2021 |
| 33795384 | Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy. | J Immunother Cancer | 2021 |
| 34281988 | CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models. | J Immunother Cancer | 2021 |
| 34214494 | Hitchhiking to brain tumours: stem cell delivery of oncolytic viruses. | Lancet Oncol | 2021 |
| 33716589 | The Effectiveness of Dichloroacetate on Human Glioblastoma Xenograft Growth Depends on Na+ and Mg2+ Cations. | Dose Response | 2021 |
| 33376098 | Delta-24-RGD, an Oncolytic Adenovirus, Increases Survival and Promotes Proinflammatory Immune Landscape Remodeling in Models of AT/RT and CNS-PNET. | Clin Cancer Res | 2021 |
| 34771600 | Clinical Value of NGS Genomic Studies for Clinical Management of Pediatric and Young Adult Bone Sarcomas. | Cancers (Basel) | 2021 |
| 34888488 | Erratum: miR-425-5p, a SOX2 target, regulates the expression of FOXJ3 and RAB31 and promotes the survival of GSCs. | Arch Clin Biomed Res | 2021 |
| 33795384 | Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy. | J Immunother Cancer | 2021 |
| 33716589 | The Effectiveness of Dichloroacetate on Human Glioblastoma Xenograft Growth Depends on Na+ and Mg2+ Cations. | Dose Response | 2021 |
| 34888488 | Erratum: miR-425-5p, a SOX2 target, regulates the expression of FOXJ3 and RAB31 and promotes the survival of GSCs. | Arch Clin Biomed Res | 2021 |
| 34771600 | Clinical Value of NGS Genomic Studies for Clinical Management of Pediatric and Young Adult Bone Sarcomas. | Cancers (Basel) | 2021 |
| 34214494 | Hitchhiking to brain tumours: stem cell delivery of oncolytic viruses. | Lancet Oncol | 2021 |
| 34281988 | CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models. | J Immunother Cancer | 2021 |